Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom
…, M Clout, J Oliver, S Gray, G Ellsbury… - The Lancet Regional …, 2023 - thelancet.com
Background There is an urgent public health need to evaluate disease severity in adults
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
Community-acquired pneumonia in the United Kingdom: a call to action
J Chalmers, J Campling, G Ellsbury, PM Hawkey… - Pneumonia, 2017 - Springer
Pneumococcal disease has a high burden in adults in the United Kingdom (UK); however,
the total burden is underestimated, principally because most cases of community-acquired …
the total burden is underestimated, principally because most cases of community-acquired …
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
…, D Weycker, M Slack, G Ellsbury… - Expert Review of …, 2022 - Taylor & Francis
Objectives Despite the current pneumococcal vaccination program in England for older adults
and adults with underlying conditions, disease burden remains high. We evaluated cost-…
and adults with underlying conditions, disease burden remains high. We evaluated cost-…
Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study
…, A Vyse, JM McLaughlin, G Ellsbury… - The Lancet Regional …, 2022 - thelancet.com
Background The emergence of COVID-19 and public health measures implemented to
reduce SARS-CoV-2 infections have both affected acute lower respiratory tract disease (aLRTD) …
reduce SARS-CoV-2 infections have both affected acute lower respiratory tract disease (aLRTD) …
Hospitalization costs of adult community-acquired pneumonia in England
…, D Mendes, MPE Slack, GF Ellsbury - Journal of Medical …, 2022 - Taylor & Francis
Objective Accurate and up-to-date figures of the cost of community-acquired pneumonia (CAP)
hospitalization are needed to understand the associated economic burden for public …
hospitalization are needed to understand the associated economic burden for public …
Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
…, A Vyse, B Mikudina, C Czudek, GF Ellsbury… - Vaccines, 2023 - mdpi.com
Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a
1+1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs, …
1+1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs, …
Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England
…, D Weycker, M Slack, G Ellsbury… - Expert Review of …, 2022 - Taylor & Francis
Background Despite use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in
England, disease burden among at-risk adults remains high. We evaluated the public health …
England, disease burden among at-risk adults remains high. We evaluated the public health …
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination …
…, G Barlow, G Kassianos, G Ellsbury - Expert Review of …, 2023 - Taylor & Francis
Introduction Pneumococcal disease (PD) significantly contributes to morbidity and mortality,
carrying substantial economic and public health burden. This article is a targeted review of …
carrying substantial economic and public health burden. This article is a targeted review of …
Identifying UK travellers at increased risk of developing pneumococcal infection: a novel algorithm
G Ellsbury, J Campling, H Madhava… - Journal of Travel …, 2021 - academic.oup.com
Background In 2016, the travel subcommittee of the UK Joint Committee on Vaccination and
Immunisation (JCVI) recommended that 13-valent PCV (PCV13) could be offered to …
Immunisation (JCVI) recommended that 13-valent PCV (PCV13) could be offered to …
A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older …
A Vyse, J Campling, C Czudek, G Ellsbury… - Expert Review of …, 2021 - Taylor & Francis
Introduction The burden of pneumococcal disease in older UK adults remains substantial.
Higher valency pneumococcal conjugate vaccines (PCVs) are currently in development with …
Higher valency pneumococcal conjugate vaccines (PCVs) are currently in development with …